<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208127</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000653</org_study_id>
    <nct_id>NCT03208127</nct_id>
  </id_info>
  <brief_title>DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant</brief_title>
  <official_title>Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Liver Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center study for the donation of HCV-positive livers to HCV negative&#xD;
      recipient patients, with preemptive, interventional treatment to prevent HCV transmission&#xD;
      upon transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be selected based on diminished likelihood of receiving a liver from the&#xD;
      waitlist within a period during which they would be likely to succumb to severe&#xD;
      comorbidities. This will be determined in part through use of a patient's MELD score, listing&#xD;
      status, and clinical judgment. To ensure maximal benefit for the recipient, only high quality&#xD;
      donor livers will be accepted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol transitioned to standard of care, no funding available to continue support of research&#xD;
    work or data analysis&#xD;
  </why_stopped>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Actual">June 4, 2021</completion_date>
  <primary_completion_date type="Actual">June 4, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Negative HCV viral RNA at 12 weeks after the last dose of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (based on number of adverse events and out of range lab values) of direct acting antiviral</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety and tolerability of direct acting antiviral therapy in the liver transplant patient will be monitored by quantifying the number of treatment related adverse events per patient and evaluating out of range laboratory results as compared to baseline/pretreatment values per patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>End Stage Liver Disease</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment with Direct Acting Antiviral Fixed Dose Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of HCV treatment with medically appropriate direct acting antiviral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with Direct Acting Antiviral tablet</intervention_name>
    <description>HCV Treatment for 12 Weeks</description>
    <arm_group_label>Treatment with Direct Acting Antiviral Fixed Dose Combination</arm_group_label>
    <other_name>DAA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient is Age ≥ 18 years&#xD;
&#xD;
          -  Met MGH transplant center criteria, listed for liver transplant&#xD;
&#xD;
          -  HCV naïve&#xD;
&#xD;
          -  Able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  HIV positivity&#xD;
&#xD;
          -  Need for dual organ transplant&#xD;
&#xD;
          -  Any contra-indication to liver transplantation per center protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masschusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond Chung</investigator_full_name>
    <investigator_title>Director of Hepatology</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Epclusa</keyword>
  <keyword>ESLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Coded data is anticipated to be shared with potential collaborators.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Anticipated that data from the study will become available within 6 months after the final patient completes the primary study endpoint (12 weeks post treatment)</ipd_time_frame>
    <ipd_access_criteria>Data would only be shared with IRB approved collaborators.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

